PL3129406T3 - Skoniugowane związki zawierające przeciwciała modyfikowane cysteiną - Google Patents
Skoniugowane związki zawierające przeciwciała modyfikowane cysteinąInfo
- Publication number
- PL3129406T3 PL3129406T3 PL15777039T PL15777039T PL3129406T3 PL 3129406 T3 PL3129406 T3 PL 3129406T3 PL 15777039 T PL15777039 T PL 15777039T PL 15777039 T PL15777039 T PL 15777039T PL 3129406 T3 PL3129406 T3 PL 3129406T3
- Authority
- PL
- Poland
- Prior art keywords
- cysteine
- engineered antibodies
- conjugated compounds
- conjugated
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461978481P | 2014-04-11 | 2014-04-11 | |
PCT/US2015/025237 WO2015157595A1 (en) | 2014-04-11 | 2015-04-10 | Conjugated compounds comprising cysteine-engineered antibodies |
EP15777039.7A EP3129406B1 (en) | 2014-04-11 | 2015-04-10 | Conjugated compounds comprising cysteine-engineered antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3129406T3 true PL3129406T3 (pl) | 2019-07-31 |
Family
ID=54288421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL15777039T PL3129406T3 (pl) | 2014-04-11 | 2015-04-10 | Skoniugowane związki zawierające przeciwciała modyfikowane cysteiną |
Country Status (20)
Country | Link |
---|---|
US (2) | US10744204B2 (pl) |
EP (1) | EP3129406B1 (pl) |
JP (1) | JP6685924B2 (pl) |
CN (1) | CN106459205B (pl) |
AU (1) | AU2015243380B2 (pl) |
BR (1) | BR112016023436A2 (pl) |
CA (1) | CA2944784A1 (pl) |
CY (1) | CY1122155T1 (pl) |
DK (1) | DK3129406T3 (pl) |
ES (1) | ES2719584T3 (pl) |
HR (1) | HRP20190486T1 (pl) |
HU (1) | HUE041976T2 (pl) |
LT (1) | LT3129406T (pl) |
PL (1) | PL3129406T3 (pl) |
PT (1) | PT3129406T (pl) |
RS (1) | RS58440B1 (pl) |
RU (1) | RU2711485C2 (pl) |
SI (1) | SI3129406T1 (pl) |
TR (1) | TR201903526T4 (pl) |
WO (1) | WO2015157595A1 (pl) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9518087B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
JP6744227B2 (ja) | 2014-02-21 | 2020-08-19 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ(ウペエフエル)Ecole Polytechnique Federale de Lausanne (EPFL) | 糖標的化治療剤 |
US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
US10160812B2 (en) | 2014-04-11 | 2018-12-25 | Medimmune, Llc | Bispecific HER2 antibodies |
US10975112B2 (en) * | 2015-06-16 | 2021-04-13 | Hangzhou Dac Biotech Co., Ltd. | Linkers for conjugation of cell-binding molecules |
MD3313845T2 (ro) * | 2015-06-29 | 2021-02-28 | Immunogen Inc | Conjugați cu anticorpi având cisteină modificată prin inginerie genetică |
PL3374398T3 (pl) * | 2015-11-10 | 2020-08-24 | Medimmune, Llc | Cząsteczki wiążące swoiste dla ASCT2 i ich zastosowanie |
MX2018006218A (es) | 2015-12-04 | 2018-09-05 | Seattle Genetics Inc | Conjugados de compuestos de tubulisina cuaternizada. |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
EA201891482A1 (ru) | 2015-12-21 | 2018-12-28 | Бристол-Маерс Сквибб Компани | Модифицированные антитела для сайт-специфической конъюгации |
DE102016106271B4 (de) * | 2016-04-06 | 2018-03-29 | Axagarius Gmbh & Co. Kg | Aufreinigung von Nukleinsäure aus einer Nukleinsäure und Endotoxin enthaltenden Probe |
KR20230149857A (ko) | 2016-07-07 | 2023-10-27 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
CN106938051B (zh) | 2016-08-22 | 2019-10-11 | 复旦大学 | 靶向于组织因子的抗体-药物偶联物 |
JP7217700B2 (ja) | 2016-09-13 | 2023-02-03 | アラーガン、インコーポレイテッド | 安定化非タンパク質クロストリジウム毒素組成物 |
CN107789630A (zh) * | 2016-10-08 | 2018-03-13 | 四川百利药业有限责任公司 | 半胱氨酸改造的抗体‑毒素偶联物及其制备方法 |
JOP20190095A1 (ar) | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y |
CA3041533A1 (en) * | 2016-11-07 | 2018-05-11 | Seattle Genetics, Inc. | Distribution of engineered-cysteine caps |
BR112019015044A2 (pt) * | 2017-02-08 | 2020-03-10 | Pfizer Inc. | Processo de produção em grande escala para cisteínas de anticorpo capeadas e não capeadas e seu uso na conjugação de proteínas terapêuticas |
MX2019010028A (es) | 2017-02-28 | 2019-10-14 | Seattle Genetics Inc | Anticuerpos con cisteina mutada por conjugacion. |
EP3381474A1 (en) | 2017-03-27 | 2018-10-03 | Alfasigma S.p.A. | Histone deacetylase inhibitors-based antibody drug conjugates (adcs) and use in therapy |
JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
US10093741B1 (en) | 2017-05-05 | 2018-10-09 | Fusion Pharmaceuticals Inc. | IGF-1R monoclonal antibodies and uses thereof |
WO2018204872A2 (en) | 2017-05-05 | 2018-11-08 | Fusion Pharmaceuticals Inc. | Igf-1r monoclonal antibodies and uses thereof |
RU2019139432A (ru) | 2017-05-05 | 2021-06-07 | Сентр фор Проуб Девелопмент энд Коммерсиализэйшн | Фармакокинетическая оптимизация бифункциональных хелатов и их применение |
CA3065171A1 (en) * | 2017-06-05 | 2018-12-13 | Janssen Biotech, Inc. | Engineered multispecific antibodies and other multimeric proteins with asymmetrical ch2-ch3 region mutations |
WO2018232176A1 (en) | 2017-06-16 | 2018-12-20 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
SG11202008821PA (en) * | 2017-06-20 | 2020-10-29 | Sichuan Baili Pharm Co Ltd | Screening of fixed-point coupling sites of cysteine-modified antibody-toxin conjugate (tdc) |
CN107167540B (zh) * | 2017-07-08 | 2019-07-30 | 万舒(北京)医药科技有限公司 | 测定人尿液生物样品中的DTPA-Zn的方法 |
DK3668874T3 (da) | 2017-08-18 | 2022-02-14 | Medimmune Ltd | Pyrrolobenzodiazepin-konjugater |
JP2020532543A (ja) * | 2017-09-02 | 2020-11-12 | アッヴィ・インコーポレイテッド | 抗egfr抗体薬物コンジュゲート(adc)及びその使用 |
RU2020112280A (ru) * | 2017-09-02 | 2021-10-05 | Эббви Инк. | Конъюгаты анти-egfr антитело-лекарственное средство (adc) и их применение |
CN111683963B (zh) * | 2017-10-03 | 2024-03-29 | 默克专利有限公司 | 半胱氨酸工程化的抗原结合分子 |
US20200239575A1 (en) * | 2017-10-06 | 2020-07-30 | University Of Utah Research Foundation | A fusion protein for targeted therapy of autoimmune disease |
WO2019071150A1 (en) * | 2017-10-06 | 2019-04-11 | University Of Utah Research Foundation | FUSION PROTEIN FOR TARGETED THERAPY OF AUTOIMMUNE DISEASE |
KR20200086312A (ko) * | 2017-11-08 | 2020-07-16 | 야페이 상하이 바이오로그 메디신 사이언스 앤드 테크놀로지 컴퍼니 리미티드 | 생체분자의 컨쥬게이트 및 이의 용도 |
ES2920123T3 (es) | 2017-11-14 | 2022-08-01 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
EP3873534A1 (en) * | 2018-10-29 | 2021-09-08 | Mersana Therapeutics, Inc. | Cysteine engineered antibody-drug conjugates with peptide-containing linkers |
CN109540859B (zh) * | 2018-11-27 | 2021-02-09 | 上海交通大学 | 一种水体中抗生素的分析和含量预测方法 |
EP3924378A4 (en) | 2019-02-15 | 2023-04-05 | WuXi Biologics Ireland Limited | METHODS FOR THE PRODUCTION OF ANTIBODY-DRUG CONJUGATES WITH IMPROVED HOMOGENEITY |
CA3130794A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
EP3941527A1 (en) * | 2019-03-21 | 2022-01-26 | ImmunoGen, Inc. | Methods of preparing cell-binding agent-drug conjugates |
CN114096280A (zh) | 2019-07-12 | 2022-02-25 | 俄勒冈健康与科学大学 | 用于共同递送有丝分裂激酶抑制剂和免疫检查点抑制剂的治疗构建体 |
US20220249389A1 (en) | 2019-07-12 | 2022-08-11 | Oregon Health & Science University | Immunotherapeutic constructs and methods of their use |
EP4003425A2 (en) * | 2019-07-25 | 2022-06-01 | Sapreme Technologies B.V. | Bioactive saponin linked to a functional moiety |
EP3789401A1 (en) | 2019-09-03 | 2021-03-10 | Gamamabs Pharma | Amhrii-binding antibody drug conjugates and their use thereof in the treatment of cancers |
CN115515643A (zh) * | 2020-02-28 | 2022-12-23 | 建新公司 | 用于优化的药物缀合的经修饰的结合多肽 |
EP4117730A1 (en) * | 2020-06-24 | 2023-01-18 | Sapreme Technologies B.V. | Conjugate of saponin and single-domain antibody, pharmaceutical composition comprising said conjugate, therapeutic use thereof |
CN111978571B (zh) * | 2020-07-09 | 2021-08-03 | 北京师范大学 | 一种荧光可调的含铕配位聚合物水凝胶薄膜 |
CN113416249B (zh) * | 2020-10-21 | 2023-04-07 | 北京智仁美博生物科技有限公司 | 针对破伤风毒素的组合物 |
UY39610A (es) | 2021-01-20 | 2022-08-31 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
RU2770003C1 (ru) * | 2021-04-05 | 2022-04-14 | Федеральное государственное унитарное предприятие «Государственный научно-исследовательский институт особо чистых биопрепаратов» Федерального медико-биологического агентства | Моноклональное антитело к С-концевому фрагменту антимюллерова гормона |
GB202105187D0 (en) | 2021-04-12 | 2021-05-26 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
GB202105186D0 (en) | 2021-04-12 | 2021-05-26 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
WO2022232246A1 (en) * | 2021-04-28 | 2022-11-03 | Ngm Biopharmaceuticals, Inc. | Multimerization of binding molecules having an antibody constant region variant |
RU2768044C1 (ru) * | 2021-12-28 | 2022-03-23 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Экспрессионный вектор на основе аденоассоциированного вируса, обладающий защитными свойствами против интоксикации, вызванной ботулиническим нейротоксином типа А |
CN115177751B (zh) * | 2022-03-16 | 2023-07-04 | 北京药明博锐生物科技有限公司 | 缀合物、其制备方法和用途 |
WO2023240067A2 (en) * | 2022-06-07 | 2023-12-14 | Ngb Biopharmaceuticals, Inc. | Multimerization of binding molecules having an antibody constant region variant and mutations that reduce effector functions |
CN116650660B (zh) * | 2023-07-27 | 2023-11-03 | 上海偌妥生物科技有限公司 | 制备抗体偶联小分子药物的方法及其应用 |
CN117198390B (zh) * | 2023-09-08 | 2024-03-12 | 中国科学院广州生物医药与健康研究院 | 通过设计和改造二硫键交联位点的slc膜蛋白复合物的制备方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
AU2004282984B2 (en) * | 2003-11-13 | 2011-07-14 | Hanmi Science Co., Ltd. | Protein complex using immunoglobulin fragment andmethod for the preparation thereof |
AU2006304387A1 (en) | 2005-10-14 | 2007-04-26 | Medimmune, Llc | Cell display of antibody libraries |
CA2652945C (en) * | 2006-05-30 | 2015-06-02 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
ES2523915T5 (es) * | 2006-12-01 | 2022-05-26 | Seagen Inc | Agentes de unión a la diana variantes y usos de los mismos |
EP2244729B1 (en) * | 2008-01-18 | 2016-11-02 | MedImmune, LLC | Cysteine engineered antibodies for site-specific conjugation |
MX2011012665A (es) * | 2009-06-04 | 2012-03-07 | Novartis Ag | Metodos para identificacion de sitios para conjugacion de igg. |
JP5918129B2 (ja) * | 2009-06-22 | 2016-05-18 | メディミューン,エルエルシー | 部位特異的共役のための操作されたFc領域 |
WO2013055990A1 (en) | 2011-10-14 | 2013-04-18 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
EP2776061B1 (en) * | 2011-11-07 | 2019-08-14 | MedImmune, LLC | Multispecific and multivalent binding proteins and uses thereof |
CN113527469A (zh) * | 2012-02-09 | 2021-10-22 | 中外制药株式会社 | 抗体的Fc区变异体 |
CN115925957A (zh) * | 2013-02-08 | 2023-04-07 | Irm责任有限公司 | 用于修饰抗体以制备免疫缀合物的特定位点 |
MA51447A (fr) * | 2017-08-01 | 2020-06-10 | Medimmune Llc | Conjugué anticorps monoclonal-médicament dirigé contre bcma |
CN110713666B (zh) * | 2018-07-13 | 2022-03-18 | 杭州星庐科技有限公司 | 一种含氯橡胶组合物及其应用和制备方法 |
-
2015
- 2015-04-10 CA CA2944784A patent/CA2944784A1/en not_active Abandoned
- 2015-04-10 US US15/302,036 patent/US10744204B2/en active Active
- 2015-04-10 SI SI201530647T patent/SI3129406T1/sl unknown
- 2015-04-10 WO PCT/US2015/025237 patent/WO2015157595A1/en active Application Filing
- 2015-04-10 ES ES15777039T patent/ES2719584T3/es active Active
- 2015-04-10 TR TR2019/03526T patent/TR201903526T4/tr unknown
- 2015-04-10 HU HUE15777039A patent/HUE041976T2/hu unknown
- 2015-04-10 AU AU2015243380A patent/AU2015243380B2/en active Active
- 2015-04-10 RU RU2016144146A patent/RU2711485C2/ru active
- 2015-04-10 LT LTEP15777039.7T patent/LT3129406T/lt unknown
- 2015-04-10 RS RS20190317A patent/RS58440B1/sr unknown
- 2015-04-10 EP EP15777039.7A patent/EP3129406B1/en active Active
- 2015-04-10 CN CN201580019243.2A patent/CN106459205B/zh active Active
- 2015-04-10 JP JP2016561655A patent/JP6685924B2/ja active Active
- 2015-04-10 PT PT15777039T patent/PT3129406T/pt unknown
- 2015-04-10 PL PL15777039T patent/PL3129406T3/pl unknown
- 2015-04-10 BR BR112016023436A patent/BR112016023436A2/pt not_active IP Right Cessation
- 2015-04-10 DK DK15777039.7T patent/DK3129406T3/en active
-
2019
- 2019-03-11 HR HRP20190486TT patent/HRP20190486T1/hr unknown
- 2019-04-09 CY CY20191100390T patent/CY1122155T1/el unknown
-
2020
- 2020-08-14 US US16/993,376 patent/US20210069341A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HUE041976T2 (hu) | 2019-06-28 |
SI3129406T1 (sl) | 2019-04-30 |
RS58440B1 (sr) | 2019-04-30 |
AU2015243380A1 (en) | 2016-11-10 |
CN106459205B (zh) | 2021-04-09 |
ES2719584T3 (es) | 2019-07-11 |
BR112016023436A2 (pt) | 2017-10-17 |
PT3129406T (pt) | 2019-04-24 |
DK3129406T3 (en) | 2019-04-01 |
HRP20190486T1 (hr) | 2019-05-31 |
JP2017512486A (ja) | 2017-05-25 |
CN106459205A (zh) | 2017-02-22 |
US20210069341A1 (en) | 2021-03-11 |
LT3129406T (lt) | 2019-04-10 |
EP3129406A4 (en) | 2017-12-06 |
JP6685924B2 (ja) | 2020-04-22 |
RU2711485C2 (ru) | 2020-01-17 |
EP3129406A1 (en) | 2017-02-15 |
AU2015243380B2 (en) | 2020-05-14 |
US20180169255A1 (en) | 2018-06-21 |
CY1122155T1 (el) | 2020-11-25 |
TR201903526T4 (tr) | 2019-03-21 |
CA2944784A1 (en) | 2015-10-15 |
EP3129406B1 (en) | 2019-01-09 |
WO2015157595A1 (en) | 2015-10-15 |
RU2016144146A (ru) | 2018-05-11 |
RU2016144146A3 (pl) | 2018-12-14 |
US10744204B2 (en) | 2020-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL252004A0 (en) | Ether-substituted antibody | |
IL250583A0 (en) | Anti-tigit antibodies | |
PL3129406T3 (pl) | Skoniugowane związki zawierające przeciwciała modyfikowane cysteiną | |
SG11201703403TA (en) | Anti-tim-3 antibodies | |
SG11201703346PA (en) | Anti-tim-3 antibodies | |
IL252422A0 (en) | Effector-deficient anti-cd32a antibodies | |
IL291164A (en) | Anti-nme antibody | |
IL250374A0 (en) | Antibodies against ceramide | |
GB201410520D0 (en) | Antibody | |
HUE048088T2 (hu) | Új, netrin-1 elleni ellenanyag | |
SG11201700922YA (en) | Anti-orai1 antibody | |
IL247988A0 (en) | Antibodies against hpa–1a | |
GB201419089D0 (en) | Anti-TIM-3 antibodies | |
GB201419092D0 (en) | Anti-TIM-3 antibodies | |
GB201417614D0 (en) | Antibodies | |
GB201414270D0 (en) | Antibodies | |
GB201418776D0 (en) | Antibody | |
GB201413745D0 (en) | Antibody | |
GB201405775D0 (en) | Antibodies | |
GB201411319D0 (en) | Antibody | |
GB201401200D0 (en) | Antibodies | |
GB201407535D0 (en) | Antibody Drug - Conjugates |